EGFR and non-small cell lung carcinoma: The most noteworthy observation to date is that AXL is upregulated by EGFR-TKIs and induces endogenous mutators, such as components involving error-prone DNA replication, and drives the transition from drug-tolerant persister to resister in EGFRM NSCLC cells [16].